Qing Xi Ooi, Ph.D.

Senior Consultant

Portrait-of-Qing-Xi-Ooi-Pharmetheus

Bio

  • Joined Pharmetheus in 2019, actively working in client projects and serving as Deputy Project Portfolio Team Leader
  • Expertise includes pharmacometrics and model-informed drug development in therapeutic areas such as ophthalmology
  • Previously worked as B.Pharm. course demonstrator and supervisor at the University of Otago, New Zealand, where she provided tutoring on pharmacokinetics and statistics as well as supervision on pharmacometrics projects, and as a clinical research scientist at the National Clinical Research Centre, Malaysia
  • M.Pharm. (2010) from the University of Manchester, UK, Ph.D. in Pharmacometrics (2018) from the University of Otago, New Zealand
LinkedInGoogle Scholar

Pharmetheus affiliated publications

A tutorial on pharmacometric Markov modelsRituximab PK and PD evaluation based on a study in diffuse large B-cell lymphoma: influence of tumor size on PK and assessment of PK similarityBounded integer model-based analysis of psoriasis area and severity index in patients with moderate-to-severe plaque psoriasis receiving BI 730357 treatmentExploring the relationship between BI 456906 exposure and change in fasting plasma glucose, fasting serum insulin, and glycated hemoglobin (HbA1c) using population PKPD modelingRituximab pharmacokinetic and pharmacokinetic–pharmacodynamic evaluation based on a study in diffuse large B-cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarityImeglimin Population Pharmacokinetics and Dose Adjustment Predictions for Renal Impairment in Japanese and Western Patients with Type 2 DiabetesBounded integer model-based analysis of psoriasis area and severity index in patients with moderate-to-severe plaque psoriasis receiving BI 730357Population Pharmacokinetic Modelling and Simulation of Imeglimin in Type 2 Diabetes Patients to Support Dose Recommendations to Patients with Renal Impairment